Mirum Pharmaceuticals, Inc. MIRM
We take great care to ensure that the data presented and summarized in this overview for Mirum Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MIRM
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.8MShares$308 Million19.27% of portfolio
-
Janus Henderson Group PLC London, X04.77MShares$216 Million0.12% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$147 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.8MShares$127 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$115 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.53MShares$114 Million2.42% of portfolio
-
Novo Holdings Hellerup, G71.5MShares$67.9 Million6.08% of portfolio
-
State Street Corp Boston, MA1.49MShares$67.7 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.45MShares$65.5 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.42MShares$64.1 Million0.01% of portfolio
Latest Institutional Activity in MIRM
Top Purchases
Top Sells
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Insider Transactions at MIRM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
2,415
-49.89%
|
$106,260
$44.45 P/Share
|
|
Mar 17
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
27,279
-16.44%
|
$1,200,276
$44.21 P/Share
|
|
Mar 17
2025
|
Peter Radovich PRESIDENT AND COO |
SELL
Open market or private sale
|
Direct |
7,879
-29.68%
|
$346,676
$44.21 P/Share
|
|
Mar 17
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
57,606
-42.81%
|
$2,534,664
$44.41 P/Share
|
|
Mar 17
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
52,900
+47.04%
|
$105,800
$2.94 P/Share
|
|
Mar 17
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
21
+0.01%
|
$903
$43.93 P/Share
|
|
Mar 15
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+23.16%
|
-
|
|
Mar 15
2025
|
Peter Radovich PRESIDENT AND COO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,440
+35.23%
|
-
|
|
Mar 15
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,315
+35.76%
|
-
|
|
Mar 14
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
528
+0.31%
|
$23,232
$44.11 P/Share
|
|
Mar 11
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
963
+0.57%
|
$41,409
$43.77 P/Share
|
|
Mar 10
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
1,335
+0.4%
|
$57,405
$43.01 P/Share
|
|
Mar 07
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
580
+0.35%
|
$24,940
$43.21 P/Share
|
|
Mar 06
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
1,335
+0.8%
|
$57,405
$43.89 P/Share
|
|
Mar 05
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
267
+0.16%
|
$11,748
$44.55 P/Share
|
|
Mar 04
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
1,335
+0.41%
|
$60,075
$45.75 P/Share
|
|
Mar 04
2025
|
Peter Radovich PRESIDENT AND COO |
SELL
Open market or private sale
|
Direct |
14,850
-29.77%
|
$668,250
$45.66 P/Share
|
|
Mar 03
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
40,000
-13.77%
|
$1,840,000
$46.9 P/Share
|
|
Mar 03
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+20.42%
|
$80,000
$2.94 P/Share
|
|
Feb 03
2025
|
Jolanda Howe SVP, GLOBAL CONTROLLER |
SELL
Open market or private sale
|
Direct |
1,064
-20.09%
|
$51,072
$48.22 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 6.71K shares |
|---|---|
| Exercise of conversion of derivative security | 292K shares |
| Grant, award, or other acquisition | 658 shares |
| Bona fide gift | 103K shares |
|---|---|
| Open market or private sale | 229K shares |